U.S. Markets open in 5 hrs 16 mins
  • S&P Futures

    3,666.00
    -1.25 (-0.03%)
     
  • Dow Futures

    29,860.00
    -8.00 (-0.03%)
     
  • Nasdaq Futures

    12,480.75
    +26.50 (+0.21%)
     
  • Russell 2000 Futures

    1,836.40
    -1.10 (-0.06%)
     
  • Crude Oil

    45.41
    +0.13 (+0.29%)
     
  • Gold

    1,843.70
    +13.50 (+0.74%)
     
  • Silver

    24.27
    +0.19 (+0.81%)
     
  • EUR/USD

    1.2117
    +0.0001 (+0.0121%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • Vix

    21.15
    +0.38 (+1.83%)
     
  • GBP/USD

    1.3402
    +0.0026 (+0.1930%)
     
  • USD/JPY

    104.2330
    -0.1910 (-0.1829%)
     
  • BTC-USD

    19,262.94
    +313.69 (+1.66%)
     
  • CMC Crypto 200

    377.34
    +12.43 (+3.41%)
     
  • FTSE 100

    6,467.01
    +3.62 (+0.06%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Jazz Pharmaceuticals: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) moved higher by 7.9% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 5.12% year over year to $4.31, which beat the estimate of $4.08.

Revenue of $600,888,000 rose by 11.75% from the same period last year, which beat the estimate of $577,580,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $12.20 and $13.00.

The upcoming fiscal year's revenue expected to be between $2,320,000,000 and $2,380,000,000.

How To Listen To The Conference Call

Date: Nov 02, 2020

View more earnings on JAZZ

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/48nkgo6h

Price Action

Company's 52-week high was at $156.26

52-week low: $86.88

Price action over last quarter: Up 28.44%

Company Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.